Merlin Rietschel
Manager Regulatory & Technical Affairs, Eucomed
Merlin Rietschel joined Eucomed in January 2011 and is the manager for Technical and Regulatory Affairs. Prior to this, he held various positions within international pharmaceutical companies (GlaxoSmithKline Biologicals and Bristol-Myers Squibb) and at the European Medicines Agency (EMA) in London, UK. He has over 8 years of experience in the field of European regulatory affairs and dealt successfully with an extensive number of regulatory submissions in life-cycle management and with marketing authorisation applications.
Merlin was raised in Germany where he received a French/German multicultural education. He also lived in the United States and has lived in Belgium since 1995. He has a Masters degree in pharmaceutical science from the Université Catholique de Louvain in Belgium, as well as a post-graduate degree in pharmaceutical industry. A German and French national, he is also fluent in English.
2 blogs from the author
Posted on 02.07.2012
Toward the best possible solution in EU medical device labelling
In summer of 2011, the EU’s Central Management Committee’s (CMC) published “Decision No 3”, requiring the placement on medical devices of the full postal address of manufacturers and authorised representatives. Since then, Decision No 3 has had the European medtech industry scratching its head in confusion. As we see it, the adoption of the decision has already led to great legal uncertainty, and implementing it in its current form would serve only to increase bureaucracy and additional, unnecessary costs.
Posted on 10.04.2012
Let’s flip the European innovation model on its head
Innovation is synonymous with progress. Embracing innovation means embracing the need to improve the sustainability and efficiency of healthcare systems by encouraging new business models, unlocking new market opportunities and improving health outcomes. Uptake of innovation in technology and services, however, could be quicker on the European healthcare scene, with myriad barriers currently standing in the way.
Medtech Views
Curated by
